Compound
VC Fund
New York, United States
Compound is a venture capital firm that invests in bleeding-edge technology built by outliers. They have partnered with elite operators that understand the intricacies of many different industries and various components of businesses, that help them navigate the complex systems in which each startup lives by removing roadblocks and compoundinggrowth.Compound is based in New York City.
- Total investments:
- 241
- Last investment:
- Lead investor:
- 14%
- Fund size:
- $50M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Compound invests in
Stages Compound invests in
Countries Compound invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 9 contacts → | |||
Round size
- Seed
- $1.2M–$7.2M
- Series A
- $1.4M–$21M
- Series B
- $3.5M–$100M
Investment Focus
Industry
- Software 39 (16%)
- Artificial Intelligence 24 (10%)
- Information Technology 19 (8%)
- FinTech 17 (7%)
- Internet 17 (7%)
Stage
- Seed 100 (41%)
- Series A 42 (17%)
- Series B 17 (7%)
- Funding Round 17 (7%)
- Pre-Seed 15 (6%)
Country
- United States 133 (55%)
- United Kingdom 7 (3%)
- Canada 3 (1%)
- Germany 2 (1%)
- Cayman Islands 2 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Dan Zigmond
Board Partner
|
Board Partner | Total investments: 1 | Find email | |
David Hirsch
Managing Partner
|
Managing Partner | Total investments: 17 | Find email | |
Josh Nussbaum
EIR
|
EIR | Total investments: 2 | Find email | |
Maddy Mestman
Contracted
|
Contracted | Total investments: 0 | Find email | |
Michael Dempsey
General Partner; Partner
|
General Partner; Partner | Total investments: 8 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Polyphron builds an autonomous tissue foundry platform for scalable, reproducible human tissue manufacturing. The company uses induced pluripotent stem cells, AI models, and automation to engineer graftable human tissues across cortical, cardiac, and other tissue contexts. Its platform integrates developmental single-cell atlases, high-throughput3D tissue experiments, and active learning to optimize tissue structure and polarity. Polyphron develops biomanufacturing systems for difficult-to-produce proteins, high-fidelity safety and efficacy screening tissues, and immune-compatible iPSC-derived grafts intended to restore tissue function and support regenerative medicine applications. | $20M / Seed / Sep 17, 2026 | ||
| From sustainable fuels, to carbon capture, to harmful chemical removal from the environment, Orbital Materials develops and commercialises technologies that keep earth our home forever. At the core of our company is a foundation model for atoms, built by world experts in generative AI and large language models. | $49.7M / Series B / May 28, 2026 | ||
| Cycles functions as a decentralized clearinghouse and reduces outstanding short-term obligations before settlement. | $6.4M / Seed / May 21, 2026 | ||
| Polyphron builds an autonomous tissue foundry platform for scalable, reproducible human tissue manufacturing. The company uses induced pluripotent stem cells, AI models, and automation to engineer graftable human tissues across cortical, cardiac, and other tissue contexts. Its platform integrates developmental single-cell atlases, high-throughput3D tissue experiments, and active learning to optimize tissue structure and polarity. Polyphron develops biomanufacturing systems for difficult-to-produce proteins, high-fidelity safety and efficacy screening tissues, and immune-compatible iPSC-derived grafts intended to restore tissue function and support regenerative medicine applications. | Seed / Jan 01, 2026 | ||
| The Embryo Corporation is a biotech company that develops new organisms and biological traits using AI-driven genetic engineering. | Seed / Jan 01, 2026 | ||
| The General Intelligence Company is an AI based It firm offering ai agents for running autonomous businesses. | $8.7M / Seed / Oct 31, 2025 | ||
| The Clearing Company is an on-chain prediction market that aims to build an on-chain, permissionless prediction market that is compliant with regulatory standards and friendly to retail users. | $15M / Seed / Aug 28, 2025 | ||
| Pear Protocol is an innovative trading dApp built on Arbitrum. Pear allows a user to trade long-short 'pair-trades' e.g. Long $BTC / short $BNB with leverage in a seamless, capital efficient, and composable way. Users will have a unique approach to both a) trade composability and b) liquidity. | $4.1M / Seed / Jul 28, 2025 | ||
| Pheiron provides a scalable, secure, and interoperable platform for deep data-driven health management. The company focuses on improving the probability of success in drug development by leveraging causal insights on targets and populations. Pheiron uses AI to map multimodal data to diseases, aiming to enhance the understanding of diseases andinform decision-making in drug development. The platform also supports large-scale exome sequence analysis to identify sex- and age-specific factors in health management. | $4.2M / Venture - Series Unknown / Jun 20, 2025 | ||
| General Intelligence Company of New York is an artificial intelligence company taking advantage of upcoming AI developments. | $2M / Pre-Seed / Apr 14, 2025 | ||
| See all 241 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Compound invest in?
Compound invests primarily in Software, Artificial Intelligence and Information Technology startups, most often at Seed and Series A stage. Most of the 241 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Compound's check size?
Compound typically joins rounds of $1.2M–$7.2M at Seed, $1.4M–$21M at Series A and $3.5M–$100M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Compound participates in.
How do I contact Compound?
Public channels for Compound include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Compound?
The team at Compound includes Dan Zigmond (Board Partner), David Hirsch (Managing Partner) and Josh Nussbaum (EIR), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
